1. Janus kinase signaling activation mediates peritoneal inflammation and injury in vitro and in vivo in response to dialysate.
- Author
-
Dai T, Wang Y, Nayak A, Nast CC, Quang L, LaPage J, Andalibi A, and Adler SG
- Subjects
- Animals, Caspase 3 metabolism, Cell Adhesion Molecules metabolism, Cells, Cultured, Chemokine CCL2 metabolism, Epithelial Cells, Female, Humans, Hyperplasia chemically induced, Janus Kinases antagonists & inhibitors, Male, Neovascularization, Pathologic chemically induced, Nitriles, Peritoneal Dialysis adverse effects, Peritoneal Fibrosis chemically induced, Peritoneum blood supply, Peritonitis chemically induced, Phosphorylation, Protein Kinase Inhibitors pharmacology, Pyrazoles pharmacology, Pyrimidines, Rats, Time Factors, Dialysis Solutions adverse effects, Janus Kinases metabolism, Peritoneum pathology, Peritonitis metabolism, STAT1 Transcription Factor metabolism, STAT3 Transcription Factor metabolism, Signal Transduction drug effects
- Abstract
Peritoneal membrane pathology limits long-term peritoneal dialysis (PD). Here, we tested whether JAK/STAT signaling is implicated and if its attenuation might be salutary. In cultured mesothelial cells, PD fluid activated, and the pan-JAK inhibitor P6 reduced, phospho-STAT1 and phospho-STAT3, periostin secretion, and cleaved caspase-3. Ex vivo, JAK was phosphorylated in PD effluent cells from long-term but not new PD patients. MCP-1 and periostin were increased in PD effluent in long term compared with new patients. In rats, twice daily, PD fluid infusion induced phospho-JAK, mesothelial cell hyperplasia, inflammation, fibrosis, and hypervascularity after 10 days of exposure to PD fluid. Concomitant instillation of a JAK1/2 inhibitor virtually completely attenuated these changes. Thus, our studies directly implicate JAK/STAT signaling in the mediation of peritoneal membrane pathology as a consequence of PD.
- Published
- 2014
- Full Text
- View/download PDF